Hypoallergenicity of a Hydrolyzed Protein Infant Formula

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

NA

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-31

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to demonstrate hypoallergenicity of a hydrolysed protein infant formula in a population of children with confirmed cow's milk allergy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hypoallergenicity of a Hydrolyzed Rice Protein-based Formula in Infants and Young Children With Cow's Milk Protein Allergy

NCT06633289

Cow's Milk Protein Allergy

RECRUITING NA

Growth, Safety and Tolerance of a Hydrolyzed Protein Infant Formula

NCT05618704

Cow Milk Allergy

COMPLETED NA

Hypoallergenicity of a New Formula in Subjects With Cow's Milk Allergy

NCT06134466

Allergy Cow's Milk Allergy

COMPLETED NA

Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula

NCT02711163

Cow Milk Allergy

COMPLETED PHASE3

Partially Hydrolyzed Formula in Cow's Milk Protein Allergy After 6 Months of Elimination

NCT06130085

Cow's Milk Protein Allergy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study consists of a double-blind, placebo-controlled food challenge, followed by a single arm open challenge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cow's Milk Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Crossover assignment and an observational, single-arm, follow-up.

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

hydrolized protein formula

hydrolysed protein formula

Group Type EXPERIMENTAL

Hydrolyzed protein infant formula

Intervention Type OTHER

Hydrolyzed protein infant formula

Control formula

commercially available hypoallergenic infant formula

Group Type PLACEBO_COMPARATOR

commercially available hypoallergenic infant formula

Intervention Type OTHER

commercially available hypoallergenic infant formula

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydrolyzed protein infant formula

Intervention Type OTHER

commercially available hypoallergenic infant formula

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Infants and children aged up to 3 years.
2. Diagnosed with cow's milk allergy (or re-confirmed), within two months prior to the study (challenge day #1), by:

1. Physician-supervised double-blind oral food challenge; or
2. Physician-supervised open oral food challenge that elicited objective immediate allergic reactions; or
3. Report of convincing allergic reaction to cow's milk or a milk-containing food product, in conjunction with presence of milk-specific serum Immunoglobuline E (IgE) level \> 0.7 kilounit per liter (U/L) or by skin prick test (wheal size ≥ 3mm).
3. Willing to switch to a different hypoallergenic formula
4. On elimination diet (commercially available, hypoallergenic infant formula ) and free of clinical symptoms, or with controlled stable symptoms, for at least one week preceding the study (challenge day #1).
5. Expected minimal consumption of 144ml of test product/day during the open challenge.
6. Written informed consent provided by parents/guardians, according to local law.

Exclusion Criteria

1. Infants/children who are more suitable to use AAF as first-line formula, including but not limited to those with high risk of anaphylaxis (prior history of anaphylaxis and currently not using eHF) or severe forms of non-IgE-mediated CMA such as eosinophilic oesophagitis, enteropathies, or Food Protein-Induced Enterocolitis Syndrome (FPIES).
2. Diagnosis or known allergy to any of the ingredients in the test product.
3. Congenital anomalies which will interfere with oral feeding or gastrointestinal tract, other chronic diseases (including but not limited to cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, immunological and endocrine disease), major gastrointestinal disease/abnormalities, or any other medical condition that could interfere with the identification of allergic reactions.
4. (Twin / triplet) sibling of an infant/child already participating in the study.
5. Investigator's uncertainty about the willingness or ability of the subject and his/her parents to comply with the protocol requirements.
6. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.
7. Employees and/or children/family members or relatives of employees of Nutricia Research or the participating study sites.

Minimum Eligible Age

0 Days

Maximum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No